Table 2 Treatment parameters of the study population
Parameter | Study group | Control group | P value |
|---|---|---|---|
Protocol | 0.923 | ||
Agonist | 66.04% (35) | 66.87% (638) | |
Antagonist | 32.08% (17) | 31.87% (304) | |
Mild stimulation | 1.88% (1) | 1.26% (12) | |
Starting dosage | 244.58 ± 60.02 | 218.25 ± 59.30 | 0.002 |
Total GN | 2625.80 ± 916.88 | 2319.86 ± 843.94 | 0.011 |
COS duration | 10.45 ± 1.75 | 10.37 ± 1.81 | 0.736 |
FSH on HCG day | 16.24 ± 5.78 | 13.42 ± 5.09 | 0.000 |
LH on HCG day | 1.15 ± 1.03 | 1.23 ± 1.35 | 0.667 |
E2 on HCG day | 2696.93 ± 1334.92 | 2841.02 ± 1155.18 | 0.430 |
P on HCG day | 1.03 ± 0.48 | 0.90 ± 0.77 | 0.218 |
NO. of oocytes | 16.68 ± 8.29 | 18.33 ± 8.49 | 0.167 |
PGT-A Platform | 0.535 | ||
NGS | 75.5% (40) | 70.5% (673) | |
SNP | 24.5% (13) | 29.5% (281) |